Myriad Genetics Launches New Molecular Diagnostic Test

Myriad Genetics, Inc. announced that it has introduced a new product, TheraGuide 5-FU, to help predict which cancer patients are likely to suffer serious toxic reactions to the drug 5-Fluorouracil (5-FU) or the oral form of the drug, capecitabine. More than 500,000 Americans with breast cancer, colon cancer, skin cancer or head and neck cancer are treated with 5-FU each year. Approximately 30% of those patients experience severe toxicity.
CNN